mithegan xl 16 milligram prolonged release capsules
pharmathen s.a. - galantamine hydrobromide - prolonged release capsules - 16 milligram
mithegan xl 24 milligram prolonged release capsules
pharmathen s.a. - galantamine hydrobromide - prolonged release capsules - 24 milligram
quodixor 150 base milligrams film coated tablet
pharmathen s.a. - ibandronate sodium monohydrate - film coated tablet - 150 base milligrams - bisphosphonates
refaz 250 milligram film coated tablet
pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 250 milligram - fluoroquinolones
refaz 500 milligram film coated tablet
pharmathen s.a. - levofloxacin hemihydrate - film coated tablet - 500 milligram - fluoroquinolones
aripiprazole mylan pharma (previously aripiprazole pharmathen)
mylan pharmaceuticals limited - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole mylan pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.aripiprazole mylan pharma is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole mylan pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.
grepid
pharmathen s.a. - clopidogrel (as besilate) - peripheral vascular diseases; stroke; myocardial infarction - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.
sabervel
pharmathen s.a. - irbesartan - hypertension - agents acting on the renin-angiotensin system - sabervel is indicated in adults for the treatment of essential hypertension.it is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen.
matever 250mg film-coated tablets
pharmathen s.a. - levetiracetam - tablets film-coated - 250mg
sedropor 150mg film-coated tablets
pharmathen s.a. - ibandronic acid (ibandronic acid sodium monohydrate) - tablets film-coated - 150mg